Drugs In The News

Bethany Crouse, PharmD Candidate; Shalyn Quigley, PharmD Oral anticoagulants are among the most commonly prescribed medications in the United States and may be used for thromboprophylaxis in atrial fibrillation (AF) or venous thromboembolism (VTE).1 For many years, warfarin has been the preferred oral anticoagulant available for stroke prevention in AF or prophylaxis/treatment of VTE. However, 2010

By Tim Gordon and Bryan Koronowski, PharmD Candidates; Justin D. Scholl, PharmD, BCACP May 2014 The American College of Cardiology (ACC) and the American Heart Association (AHA) recently developed a new guideline for the management of hyperlipidemia. The fundamental goal of this guideline is to identify a patient’s risk for atherosclerotic cardiovascular disease (ASCVD) and

Phillip Rosel, Dhara Patel, Wendy Nguyen, Kevin Thu, PharmD Candidates; Marcus Campbell, PharmD, BC-ADM Warfarin, a vitamin K antagonist (VKA), results in the hospitalization of 1% of all patients being treated each year, and can cause fatal-bleeding in 0.3% of those treated.1 Normally used to prevent or treat venous thrombosis, warfarin can cause major bleeding events

Shalyn Quigley, PharmD; PGY1 General Practice Resident, Millcreek Community Hospital in Erie, PA When hemostatic balance is interrupted by stasis, stress, or hypercoagulabilty, patients are at risk for venous or arterial thrombosis that may require medical prophylaxis or treatment. In the low shear venous system, thrombi are composed of red blood cells trapped by fibrin

Camille Zambrana, PharmD Candidate; Marcus Campbell, PharmD, BC-ADM Patients with COPD experience exacerbations approximately 1 to 2 times per year; those with frequent episodes are reported to have a more rapid decline in overall lung function.  Exacerbations are triggered by a number of factors (i.e., exposure to pollutants and interruption of maintenance therapy), but the

Wycliffe Mugoya, PharmD Candidate; Marcus Campbell, PharmD, BC-ADM, Ryan Wargo, PharmD, BCACP Recently, FDA approved GlaxoSmithKline’s Breo Ellipta; an inhaled corticosteroid and long-acting beta agonist (ICS/LABA) combination product for long-term maintenance therapy in COPD patients. Breo Ellipta contains 100 mcg of fluticasone furoate and 25 mcg of vilanterol, which is administered via dry powder inhaler once

A Novel COPD Medication

Saturday, 02 November 2013

Keith Sawh, PharmD Candidate; Marcus Campbell, PharmD, BC-ADM Presently, no pharmacological treatment is shown to modify the rate of decline in lung function or disease progression.  Patients are commonly treated with bronchodilators to improve symptoms and reduce exacerbations: long-acting muscarinic antagonists (LAMAs) and long-acting β2-agonists (LABAs). LAMAs and LABAs can be used as monotherapy or in combination

November is COPD awareness month

Friday, 01 November 2013

Keith Sawh, PharmD Candidate; Marcus Campbell, PharmD, BC-ADM Chronic Obstructive Pulmonary Disease (COPD) is an airway disease characterized by long term progressive airflow limitation. The most common symptoms exhibited by COPD patients include dyspnea, chronic cough with sputum production, tiredness, chest tightness, and limitations of activity. The National Heart, Lung, and Blood Institute (NHLBI) estimates

Kevin Olivieri, PharmD Candidate; Michael Mueller, PhD Until recently, no FDA approved treatment was available for systemic juvenile idiopathic arthritis (sJIA), a disease from which an estimated 250,000 children suffer in the US alone.1  On May 10, 2013 the biologic interleukin-1 beta antagonist Ilaris®, (canakinumab) was approved for the treatment of sJIA in children aged 2

Eric Yeo, PharmD Candidate; Marcus Campbell, PharmD, BC-ADM Osteoporosis is a disease associated with a reduction in bone mass and an increase in skeletal fragility. It affects 10 million Americans; another 34 million are considered at risk.1 Bisphosphonates have been shown to be effective in reducing the risk of osteoporotic fragility fractures, and are widely prescribed for